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Abstract 
Background: Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with 
metastatic melanoma. Response to anti-PD-1 treatment requires pre-existing CD8+ T cells that are negatively regu-
lated by PD-1-mediated adaptive immune resistance. Unfortunately, less than half of melanoma tumours have these 
characteristics. Combining anti-PD-1 treatment with other immunomodulating treatments to activate CD8+ T cells 
is therefore of vital importance to increase response rates and long-term survival benefit in melanoma patients. Both 
preclinical and retrospective clinical data support the hypothesis that radiotherapy increases the response rates to 
anti-PD-1 treatment by stimulating the accumulation and activation of CD8+ T cells in the tumour microenviron-
ment. Combining radiotherapy with a PD-1 blocking antibody might therefore increase response rates and even 
induce long-term survival. The current phase II study will be testing these hypotheses and aims to improve local 
and distant tumour responses by exploiting the pro-immunogenic effects of radiotherapy in addition to anti-PD-1 
treatment.
Methods: The trial will be conducted in patients with metastatic melanoma. Nivolumab or pembrolizumab, both 
antibodies that target PD-1, will be administrated according to the recommended dosing schedule. Prior to the 2nd 
cycle, radiotherapy will be delivered in three fractions of 8 Gy to the largest FDG-avid metastatic lesion. The primary 
endpoint is the proportion of patients with a partial or complete response in non-irradiated metastases according to 
RECIST v1.1. Secondary endpoints include response rate according to immune related response criteria, metabolic 
response, local control and survival. To identify peripheral blood biomarkers, peripheral blood mononuclear cells and 
serum samples will be collected prospectively before, during and after treatment and subjected to flow cytometry 
and cytokine measurement.
Discussion: The current phase II trial aims at exploring the suggested benefits of combining anti-PD-1 treatment and 
radiotherapy. The translational focus on immunologic markers might be suitable for predicting efficacy and monitor-
ing the effect so to improve patient selection for future clinical applications.
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Background
Patients with metastatic melanoma had a median overall 
survival of only 6–9 months [1] until a breakthrough was 
achieved with novel immunomodulatory agents blocking 
specific immune checkpoints. Immune checkpoints, such 
as cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4), PD-1 and programmed cell death 1 ligand (PD-L1), 
are negative regulators of the immune system, that play 
critical roles in maintaining self-tolerance and modu-
lating immune responses to protect normal tissue from 
immune collateral damage. Inhibition of these immune 
checkpoints by CTLA-4 blocking agents and anti PD-L1 
antibodies is therefore able to reactivate T cells and 
restore anti-tumour immunity, resulting in impressive 
efficacy in patients with metastatic melanoma [2].
For these patients, antibodies targeting PD-1 have shown 
superior responses than those seen with CTLA-4 block-
ing agents, with response rates of 34% compared to 11% 
respectively [3]. Unfortunately, there still remain a sub-
stantial number of patients that do not obtain any clinical 
benefit. It is hypothesized that anti-tumour responses are 
limited by other immune inhibitory mechanisms present in 
the tumour microenvironment (TME). Patients who do not 
respond to PD-1 blocking agents typically have an immune 
suppressive TME hampering the activation of CD8+ cyto-
toxic T cells (CTLs). These patients may require the addi-
tion of other therapies that enhance anti-tumour immunity 
or circumvent immune inhibition. Potential candidates 
include other immunotherapies and radiotherapy.
Radiotherapy has important effects on the immune sys-
tem and is able to shift the balance from tumour immune 
evasion towards tumour control [4]. Additionally, the 
best tumour control and tumour immunity are more 
likely to be achieved with high dose per fraction radio-
therapy [5, 6]. By using stereotactic body radiotherapy 
(SBRT) we are able to safely deliver such high doses of 
radiation very precisely in a small number of fractions. 
Preclinical evidence clearly indicates that SBRT increases 
response rates and long-term survival of anti-PD-1 treat-
ment by stimulating the accumulation and activation of 
CD8+ CTLs in the TME [7–10]. Considering the deli-
cate interplay between both modalities, we have chosen 
to investigate a specific combination sequence in which 
1 cycle of anti-PD-1 treatment will precede SBRT. This 
sequence allows the creation of a more immune permis-
sive TME in which radiotherapy can induce the release 
of multiple tumour antigens causing the activation of 
tumour-specific CD8+ CTLs. The subsequent cycles 
of anti-PD-1 treatment may further stimulate the effec-
tor function of activated CD8+ CTLs by blocking the 
engagement of PD-1 with its ligand PD-L1.
The current phase II trial aims at exploring the sug-
gested benefits of this combination. Considering the 
toxicity of immune checkpoint inhibitors and their high 
economical cost, it is of utmost importance to identify 
patients who are likely to respond to these treatments 
beforehand. Unfortunately, there are currently no vali-
dated markers available to pre-identify responders, and 
even the effects of checkpoint inhibitors on circulating 
immune cells remain unknown. We therefore will moni-
tor circulating immune cells and cytokine levels, to iden-
tify the mechanism of response and resistance to therapy. 
We recently demonstrated that low levels of plasmacy-
toid dendritic cells and high expression of indoleamine 
2,3-dioxygenase (IDO) in the peripheral blood of mela-
noma patients confer a negative prognosis, independ-
ent of disease stage. Systemic IDO, PD-L1 and CTLA-4 
expression were also interconnected [11]. We will spe-
cifically focus on the relevance of these markers, as they 
could help elucidate the counter-regulatory mechanisms 
and provide predictive information.
Methods
Objectives
Primary objective
The primary objective of this trial is to determine the 
response rate as per RECIST v1.1 of the combination of 
anti-PD-1 with SBRT.
Secondary objectives
Secondary objectives are to determine the immune-
related response rate of the combination treatment, 
metabolic response, local control, progression free sur-
vival (PFS) and toxicity. We will also analyse circulating 
immune cells, cytokine levels and markers in tumour tis-
sue (if feasible) during treatment.
Trial design
This phase II trial assesses the response rates of the anti-
PD-1/SBRT combination. Nivolumab or pembrolizumab 
will be administrated according to the recommended 
dosing schedule. Prior to the 2nd cycle, SBRT will be 
delivered (24  Gy in three fractions) to the largest (max. 
diameter of 5 cm) fluorodeoxyglucose (FDG)-avid meta-
static lesion. Table 1 shows a general scheme of the trial.
This trial uses a Simon two-stage optimal design, a 
design often used for phase II cancer clinical trials [12]. 
This design allows the assessment of the efficacy of a 
combination therapy in a relatively small number of 
patients.
Outcome measures
Primary endpoint
  • Objective response rate of the non-irradiated metas-
tases as determined by the response evaluation cri-
teria in solid tumours (RECIST) v1.1 [13]. Response 
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rate will be defined as the percentage of subjects 
achieving either a complete or partial response at 
6  weeks after the start of anti-PD-1 treatment. Fur-
ther follow up imaging will be performed at the dis-
cretion of the treating physician.
Secondary endpoints
  • Objective response rate of the non-irradiated metas-
tases as determined by immune related response cri-
teria (irRC) [14].
  • Metabolic response of the irradiated and non-irradi-
ated metastases based on the European Organization 
of Research and Treatment of Cancer (EORTC) 1999 
criteria [15].
  • Local control defined as the time between local irra-
diation and the moment the irradiated lesion shows 
an increase in size of ≥20%, according to the RECIST 
V1.1, confirmed by a consecutive assessment at least 
4 weeks after first documentation.
  • PFS: two types of PFS will be defined. One as the time 
from inclusion to documented disease progression 
according to RECIST v1.1 or death from any cause. 
The other as the time from inclusion to documented 
disease progression according to irRC or death from 
any cause.
  • Acute and late toxicity due to the combination treat-
mentwill be scored using the Common terminology 
criteria for adverse events (CTCAE) version 4.0.
Exploratory endpoint
  • Immunologic responses assessed using peripheral 
blood samples and analysed with fluorescence-acti-
vated cell sorting (FACS) phenotyping, functional 
testing, ultra-performance liquid chromatography 
(UPLC) and enzyme-linked immunosorbent assay 
(ELISA). If feasible, immunologic responses will also 
be assessed on tumour tissue using IHC.
Study population
Patients with metastatic melanoma who did not receive 
previous immunotherapeutic treatment and have at least 
two measurable extracranial lesions.
Inclusion criteria
  • Before patient registration, written informed consent 
must be given according to the International Coun-
cil for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH)/Good Clini-
cal Practice (GCP), and national/local regulations.
  • Histologically confirmed diagnosis of melanoma.
  • Be able to provide tissue from an archival primary 
tissue sample or a newly obtained biopsy, for the 
evaluation of PD-L1 and other immune markers 
using immunohistochemistry (IHC).
  • At least two extracranial measurable metastatic 
lesions per RECIST v1.1 and irRC. All radiological 
studies must be performed within 28  days prior to 
registration.
  • Previous BRAF inhibitor when elevated lactate dehy-
drogenase (LDH) in patients with BRAF V600 muta-
tions is allowed.
  • Karnofsky Performance status >60.
  • Age 18 years or older.
  • Female participants of childbearing potential must be 
willing to use two methods of birth control or be sur-
gically sterile, or abstain from heterosexual activity 
for the course of the study through 120 days after the 
last dose of study treatment.
  • Female participants who are breastfeeding or plan to 
breastfeed should be instructed to discontinue nurs-
ing during treatment.
  • Male participants must agree to use an adequate 
method of contraception starting with the first dose 
of study therapy through 120 days after the last dose 
of study treatment.
  • Demonstrate adequate organ function defined as the 
following:
• Serum aspartate and alanine aminotransferase 
(AST and ALT) levels ≤2.5× upper limit of normal 
(ULN) or ≤5× ULN in patients with liver metasta-
ses.
•  Serum total bilirubin ≤1.5× ULN or direct bili-
rubin ≤ULN for patients with total bilirubin level 
>1.5 ULN.
•  Serum creatinine ≤1.5× ULN.
•  Absolute neutrophil count ≥1000/mcL.
•  Platelets ≥75,000/mcL.
•  Hemoglobin ≥9 g/dL or ≥5.6 mmol/L.
  • No history of active autoimmune disease requir-
ing systemic treatment within the past 3 months or 
documented history of clinically severe autoimmune 
Table 1 General scheme of the trial
Run-in period Study period Observation period
SBRT Three fractions of 8 Gy every other day
Anti-PD-1 treatment First cycle Second cycle Continuation
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disease, or syndrome that requires systemic steroids 
or immunosuppressive agents.
  • Subjects who have had another malignancy should 
be disease-free for 5 years, or should have a history of 
completely resected non-melanoma skin carcinoma 
or successfully treated in situ carcinoma.
  • No evidence of interstitial lung disease.
  • No uncontrolled central nervous metastases and/or 
carcinomatous meningitis.
  • No prior radiotherapy interfering with the radiother-
apy treatment in the study.
  • No concomitant therapy with interleukin-2, inter-
feron, other immunotherapy regimens, chemother-
apy, immunosuppressive agent or chronic use of sys-
temic corticosteroids.
  • No active infection requiring systemic therapy.
  • No known history of human immunodeficiency 
virus.
  • No known active Hepatitis B or Hepatitis C infection.
  • Subjects should not have received a live vaccine 
within 30 days prior to start of study treatment.
  • Subjects without a mental condition rendering the 
patient unable to understand the nature, scope and 
possible consequences of the study.
  • Subjects who are likely to comply with the protocol; 
i.e. no uncooperative attitude, no inability to return 
for follow-up visits, and likely to complete the study.
Evaluation and randomization
Patients must be restaged within 4 weeks prior to rand-
omization with an 18F-FDG Positron emission tomogra-
phy with X-ray computed tomography (PET/CT).
Intervention
SBRT
Prior to the 2nd cycle of treatment, SBRT will be deliv-
ered to the largest FDG-avid metastatic lesion (max. 
5  cm diameter). A total dose of 24  Gy will be delivered 
in two fractions with image-guided treatment verification 
and fractions will be separated >48 h and <96 h.
All patients will receive a CT simulation in supine posi-
tion with 2  mm CT slice thickness through the tumour 
site. The planning simulation should cover the target and 
all organs at risk. A typical scan length should extend at 
least 10  cm superior and inferior beyond the treatment 
field borders. Support devices to increase patient com-
fort will be chosen depending on the tumour localisation. 
The isocenter will be determined on the CT-simulator 
with marking of laser lines on the patient. Imaging data 
will be transferred to the treatment planning system. 
For all lesions, the Gross Target Volume (GTV) will be 
defined as all visible tumour by combining iconographic 
and metabolic information. No additional margin will be 
added for microscopic spread of disease. The GTV will 
be expanded with 2–5  mm to the Planning Target Vol-
ume (PTV) to account for organ motion and setup error. 
Margins depend on the site irradiated with 2  mm mar-
gins for bony lesions, 3 mm for nodes and 5 mm for other 
sites. The type of organ at risk delineated depends on the 
localization of the metastasis. A Planning Organ at Risk 
Volume (PRV) expansion of 2–5  mm will be added for 
organs at risk (OAR) and dose constraints apply to this 
PRV. It is strongly recommended that dose constraints 
not be exceeded. If a dose constraint cannot be achieved 
due to overlap of the target with an organ at risk or its 
PRV, the total dose can be lowered in order to meet the 
constraint. Treatment will be prescribed to the periphery 
of the target (80% of the dose) covering the 90% of the 
PTV. Dose constraints of organ at risks will be in accord-
ance with the recommendations of the American Asso-
ciation of Physicist in Medicine (AAPM) task group 101 
report. In case of violation of constraints to the organs at 
risk, the prescription will be adapted accordingly.
Systemic therapy
Anti-PD-1 treatment (nivolumab or pembrolizumab) will 
be administrated according to the recommended dos-
ing schedule and continued until clinical progression. 
Patients may also discontinue protocol therapy when 
unacceptable toxicity is encountered. Administration 
of anti-PD-1 treatment should be withheld for a drug-
related non-hematologic toxicity ≥grade 2 (excluding 
fatigue). The use of corticosteroids should be considered 
for management of immune-related adverse events. Once 
the patient has recovered to grade 0–1 consider increas-
ing the dosing interval in subsequent cycles by 1 week. If 
the drug-related toxicity does not resolve to grade 0–1 
within 12  weeks after onset of toxicity, discontinuation 
is recommended. Patients may also discontinue protocol 
in case of intercurrent illness, which would in the judg-
ment of the investigator affect patient safety, the ability to 
deliver treatment or by request of the patient.
Evaluation of pre‑treatment PD‑L1 expression
A PD-L1 IHC assay using Merck mouse monoclonal anti-
body clone 22C3 will be performed on archival primary 
tissue sample or a newly obtained biopsy. Hematoxylin 
& eosin staining will be reviewed for confirmation of 
tumour presence.
Evaluation of the immunological response
The study requires blood samples (EDTA and serum) before 
start of anti-PD-1 treatment, before start of SBRT, 5–7 days 
after the last dose of SBRT and at week 6. The samples will 
be analysed with FACS phenotyping, functional testing 
and ELISA. The immune response will be analysed with a 
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comprehensive immunophenotyping on peripheral blood. 
We will specifically look at the expression of immune sup-
pressive markers CTLA-4, PD-L1 and IDO. For PD-L1 
staining, we will use the mouse anti-human monoclonal 
antibody PD-L1 PE-Cy7. For intracellular staining, PBMCs 
will be fixed and permeabilized with fixation/permeabili-
zation solution, and then stained with anti-human IDO PE 
and CTLA-4 APC. Tryptophan and kynurenine, a down-
stream metabolite of IDO, in patient’s sera will be quantified 
by UPLC-mass spectrometry. We will also look at absolute 
lymphocyte count, absolute neutrophil count/absolute lym-
phocyte count, serum tryptophan, C-reactive protein and 
cytokines, frequencies of Foxp3+ regulatory T cells, den-
dritic cell and myeloid derived suppressor cell subsets, next 
to functional analysis looking at shifts in Th1/Th2/Th17 
polarization as a function of treatment [11, 16].
If feasible, tumour tissue will be analysed by IHC stain-
ing. Serial sections will be incubated with a monoclonal 
anti-FoxP3 and a monoclonal anti-IDO antibody for 1 h. 
For staining with CD3, CD8 and CD31 antibodies, an 
incubation time of 30 min will be used [17].
Follow-up
Patients will be seen before the start of each treatment cycle 
during the whole course of anti-PD-1 therapy. At each visit, 
a history and physical examination will be conducted with 
recording of the toxicity. For response evaluation, a 18F-
FDG PET/CT will be performed at week 6. For further fol-
low up, CT thorax, abdomen and pelvis or 18F-FDG PET/
CT will be performed at the treating physician’s discretion 
until disease progression or treatment discontinuation. 
Additional imaging or laboratory investigations should be 
carried out at the discretion of the treating physician, based 
on findings in the history or physical examination.
Sample size
In the first stage, 20 patients will be accrued. If there are 
five or fewer responses, the alternative hypothesis will 
be rejected and the study will be stopped. If there are 13 
or more responses, the null hypothesis will be rejected. 
Otherwise 20 additional patients will be accrued for a 
total of 40 patients (Table 2). Simon’s 2-stage Optimum 
design [18] will be used.
Data analysis
  • The goal of the proposed trial is to determine the effi-
cacy of the proposed combination sequence of anti-
PD-1 treatment and radiotherapy. The primary end-
point is the objective response rate as per RECIST 
v1.1. The null hypothesis that the true response rate 
is 0.34 [3] will be tested against a one-sided alterna-
tive. The null hypothesis will be rejected if 18 or more 
responses are observed in 40 patients.
  • PFS is defined from the day of randomization until 
progression or last follow-up. Cases will be censored 
at last follow up visit if no progression was observed. 
Multivariate analysis will be performed according to 
the Cox-Regression method.
  • For the evaluation of immunological markers over 
time, differences between groups will be tested by 
using the Friedman test. To compare proportions of 
categorical variables, the Pearson’s Chi2 test or Fish-
er’s Exact test will be used. To evaluate correlations, 
Spearman correlation coefficients will be calculated. 
All statistical analyses will be done on an ‘intention-
to-treat’ basis and performed using SPSS 24.0 (SPSS 
Inc, Chicago, IL, USA), a P-value less than 0.05 will 
be considered statistically significant.
Study approval
This trial is approved by the Ethics committee of the 
Ghent University Hospital (EC2016/0540) and is regis-
tered on clinicaltrials.gov (NCT 02821182).
Discussion
Although current immunotherapeutic treatment options 
have led to an important breakthrough in patients with 
metastatic melanoma, they still fail to induce long-lasting 
clinical benefit in the majority of patients. We hypothesize 
that combining anti-PD-1 treatment with radiotherapy 
might result in improved clinical response rates and PFS 
compared to anti-PD-1 treatment in monotherapy. Both 
preclinical and retrospective clinical data support this 
hypothesis. The current study is an innovative translational 
phase II design translating preclinical data to the clinic. 
By using a Simon two-stage optimal design, the study will 
allow the assessment of the efficacy of a combination ther-
apy in a relatively small number of patients before embark-
ing on more expensive randomized trials. In addition, the 
translational focus on immunologic markers might be suit-
able for identifying mechanisms of response and resistance 
to therapy, resulting in predictors for efficacy and improved 
patient selection for future clinical applications.
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